SCNI

Scinai Immunotherapeutics (SCNI.US) tumbled more than 8% during regular trading to $0.5179.

The stock is down 55.35% over the past ten sessions and down 92.73% year to date. It sits 96.66% below its 52-week high of US$15.49. Volume was 6.01 times its average.

The Nasdaq Composite is down 1.32% over the past five sessions and up 12.22% year to date.

The company completed a private placement and warrant inducement transaction totaling approximately $4 million on Oct. 16, 2026, issuing American depositary shares or pre-funded warrants to an institutional investor. The proceeds will be used to advance its contract development and manufacturing organization projects and immunotherapy pipeline.

Based on public media reports. AI-generated; not investment advice.